

# Jan Holmgren

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8035523/jan-holmgren-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203  
papers

12,342  
citations

60  
h-index

106  
g-index

211  
ext. papers

13,436  
ext. citations

6.9  
avg, IF

6.13  
L-index

#	Paper	IF	Citations
203	Mucosal immunity and vaccines. <i>Nature Medicine</i> , <b>2005</b> , 11, S45-53	50.5	1062
202	Evidence for several waves of global transmission in the seventh cholera pandemic. <i>Nature</i> , <b>2011</b> , 477, 462-5	50.4	492
201	Actions of cholera toxin and the prevention and treatment of cholera. <i>Nature</i> , <b>1981</b> , 292, 413-17	50.4	475
200	Identification of Escherichia coli heat-labile enterotoxin by means of a ganglioside immunosorbent assay (GM1-ELISA) procedure. <i>Current Microbiology</i> , <b>1978</b> , 1, 19-23	2.4	326
199	Protection against cholera in breast-fed children by antibodies in breast milk. <i>New England Journal of Medicine</i> , <b>1983</b> , 308, 1389-92	59.2	278
198	The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. <i>European Journal of Immunology</i> , <b>1992</b> , 22, 2277-81	6.1	260
197	Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. <i>Lancet, The</i> , <b>2005</b> , 366, 44-9	4.0	259
196	Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. <i>Vaccine</i> , <b>1993</b> , 11, 1179-84	4.1	255
195	Field trial of oral cholera vaccines in Bangladesh. <i>Lancet, The</i> , <b>1986</b> , 2, 124-7	4.0	255
194	Comparison of the tissue receptors for Vibrio cholerae and Escherichia coli enterotoxins by means of gangliosides and natural cholera toxoid. <i>Infection and Immunity</i> , <b>1973</b> , 8, 851-9	3.7	216
193	Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. <i>Vaccine</i> , <b>2003</b> , 21 Suppl 2, S89-95	4.1	210
192	Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. <i>American Journal of Epidemiology</i> , <b>1985</b> , 121, 791-6	3.8	205
191	Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh. <i>Journal of Clinical Microbiology</i> , <b>2006</b> , 44, 4211-3	9.7	197
190	Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2009</b> , 374, 1694-702	4.0	192
189	Cholera. <i>Lancet, The</i> , <b>2017</b> , 390, 1539-1549	4.0	188
188	5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases, The</i> , <b>2013</b> , 13, 1050-6	25.5	166
187	Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. <i>Vaccine</i> , <b>2007</b> , 25, 8598-610	4.1	157

186	Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2010</b> , 30, 946-52	9.4	153
185	Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. <i>Infection and Immunity</i> , <b>2001</b> , 69, 7481-6	3.7	143
184	Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. <i>Infection and Immunity</i> , <b>1998</b> , 66, 514-20	3.7	142
183	Mucosal immunity: implications for vaccine development. <i>Immunobiology</i> , <b>1992</b> , 184, 157-79	3.4	140
182	Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. <i>Immunology Letters</i> , <b>2005</b> , 97, 181-8	4.1	138
181	A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. <i>Journal of Virology</i> , <b>2003</b> , 77, 953-62	6.6	134
180	Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. <i>Infection and Immunity</i> , <b>2001</b> , 69, 5716-25	3.7	129
179	B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. <i>Journal of Immunology</i> , <b>2008</b> , 181, 8278-87	5.3	119
178	Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. <i>PLoS Neglected Tropical Diseases</i> , <b>2011</b> , 5, e1289	4.8	117
177	Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. <i>Current Opinion in Immunology</i> , <b>2005</b> , 17, 388-98	7.8	116
176	Vaccines against mucosal infections. <i>Current Opinion in Immunology</i> , <b>2012</b> , 24, 343-53	7.8	108
175	Recent advances in mucosal vaccines and adjuvants. <i>Current Opinion in Immunology</i> , <b>2002</b> , 14, 666-72	7.8	108
174	Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. <i>Journal of General Virology</i> , <b>2001</b> , 82, 845-853	4.9	108
173	Comparison of receptors for cholera and Escherichia coli enterotoxins in human intestine. <i>Gastroenterology</i> , <b>1985</b> , 89, 27-35	13.3	107
172	ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. <i>Journal of Infectious Diseases</i> , <b>1989</b> , 159, 770-3	7	105
171	Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. <i>Infection and Immunity</i> , <b>1998</b> , 66, 3390-6	3.7	99
170	Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. <i>Infection and Immunity</i> , <b>2003</b> , 71, 1740-7	3.7	97
169	Mechanisms of disease and immunity in cholera: a review. <i>Journal of Infectious Diseases</i> , <b>1977</b> , 136 Suppl, S105-12	7	97

168	Fixation and inactivation of cholera toxin by GM1 ganglioside. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1973</b> , 5, 77-8		96
167	Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxicogenic <i>Escherichia coli</i> enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. <i>Journal of Virology</i> , <b>2006</b> , 80, 4962-70	6.6	94
166	A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. <i>PLoS ONE</i> , <b>2008</b> , 3, e2323	3.7	94
165	Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25- CD4+ regulatory T cells. <i>Journal of Immunology</i> , <b>2006</b> , 177, 7634-44	5.3	93
164	Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic <i>Escherichia coli</i> (ETEC) vaccine administered alone and together with dmlT adjuvant in a double-blind, randomized, placebo-controlled Phase I study. <i>Vaccine</i> , <b>2014</b> , 32, 7077-84	4.1	89
163	Development of oral vaccines against enterotoxinogenic <i>Escherichia coli</i> diarrhoea. <i>Vaccine</i> , <b>1989</b> , 7, 196-8	4.1	89
162	Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. <i>Journal of Virology</i> , <b>2001</b> , 75, 6705-9	6.6	85
161	Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. <i>Vaccine</i> , <b>1992</b> , 10, 130-2	4.1	84
160	Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. <i>Vaccine</i> , <b>2007</b> , 25, 1149-55	4.1	82
159	Human circulating specific antibody-forming cells after systemic and mucosal immunizations: differential homing commitments and cell surface differentiation markers. <i>European Journal of Immunology</i> , <b>1995</b> , 25, 322-7	6.1	82
158	Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. <i>Infection and Immunity</i> , <b>1999</b> , 67, 2884-90	3.7	82
157	Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. <i>Journal of Immunology</i> , <b>2009</b> , 183, 7851-9	5.3	80
156	In vivo adjuvant-induced mobilization and maturation of gut dendritic cells after oral administration of cholera toxin. <i>Journal of Immunology</i> , <b>2004</b> , 173, 5103-11	5.3	80
155	Identification of a mannose-binding pilus on <i>Vibrio cholerae</i> El Tor. <i>Microbial Pathogenesis</i> , <b>1991</b> , 11, 433-41	3.8	79
154	Cholera Toxin Induces a Transient Depletion of CD8+ Intraepithelial Lymphocytes in the Rat Small Intestine as Detected by Microarray and Immunohistochemistry. <i>Infection and Immunity</i> , <b>2005</b> , 73, 7788-7788	3.7	78
153	Safety and immunogenicity of an oral inactivated enterotoxigenic <i>Escherichia coli</i> vaccine. <i>Vaccine</i> , <b>1998</b> , 16, 255-60	4.1	77
152	Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nephropathy. <i>Kidney International</i> , <b>1996</b> , 50, 952-61	9.9	72
151	Cholera toxin - a foe & a friend. <i>Indian Journal of Medical Research</i> , <b>2011</b> , 133, 153-63	2.9	70

150	Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. <i>Journal of Immunology</i> , <b>2003</b> , 170, 1586-92	5.3	69
149	Receptor-specific large-scale purification of cholera toxin on silica beads derivatized with lysoGM1 ganglioside. <i>FEBS Journal</i> , <b>1981</b> , 113, 249-58		69
148	Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. <i>Vaccine</i> , <b>2009</b> , 27, 6887-93	4.1	66
147	Cloning and sequencing of <i>Vibrio cholerae</i> mannose-sensitive haemagglutinin pilin gene: localization of mshA within a cluster of type 4 pilin genes. <i>Molecular Microbiology</i> , <b>1994</b> , 13, 109-18	4.1	66
146	Breast feeding and the risk of severe cholera in rural Bangladeshi children. <i>American Journal of Epidemiology</i> , <b>1990</b> , 131, 400-11	3.8	64
145	Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. <i>European Journal of Immunology</i> , <b>2003</b> , 33, 224-32	6.1	63
144	Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. <i>Vaccine</i> , <b>2006</b> , 24, 4297-303	4.1	61
143	Broad up-regulation of innate defense factors during acute cholera. <i>Infection and Immunity</i> , <b>2007</b> , 75, 2343-50	3.7	60
142	Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. <i>Infection and Immunity</i> , <b>2001</b> , 69, 4125-8	3.7	60
141	A double mutant heat-labile toxin from <i>Escherichia coli</i> , LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against <i>Helicobacter pylori</i> infection. <i>Infection and Immunity</i> , <b>2013</b> , 81, 1532-40	3.7	59
140	Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. <i>Infection and Immunity</i> , <b>1998</b> , 66, 5889-96	3.7	58
139	CD4+CD25+ suppressor T cells regulate pathogen induced inflammation and disease. <i>FEMS Immunology and Medical Microbiology</i> , <b>2005</b> , 44, 121-7		56
138	Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-beta-secreting cells and suppressing chemokine expression. <i>International Immunology</i> , <b>2000</b> , 12, 1449-57	4.9	54
137	Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin. <i>Journal of Immunology</i> , <b>2006</b> , 176, 2749-57	5.3	53
136	Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. <i>Expert Review of Vaccines</i> , <b>2003</b> , 2, 205-17	5.2	53
135	Natural killer cells and <i>Helicobacter pylori</i> infection: bacterial antigens and interleukin-12 act synergistically to induce gamma interferon production. <i>Infection and Immunity</i> , <b>2005</b> , 73, 1482-90	3.7	53
134	Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 1628-34		53
133	Sublingual immunization protects against <i>Helicobacter pylori</i> infection and induces T and B cell responses in the stomach. <i>Infection and Immunity</i> , <b>2010</b> , 78, 4251-60	3.7	52

132	CD11c(high )dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization. <i>Journal of Immunology</i> , <b>2009</b> , 183, 5032-41	5.3	51
131	Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. <i>Vaccine</i> , <b>1993</b> , 11, 929-34	4.1	51
130	Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling. <i>Journal of Immunology</i> , <b>2015</b> , 194, 3829-39	5.3	50
129	Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine. <i>Infection and Immunity</i> , <b>2000</b> , 68, 5749-55	3.7	50
128	New-generation vaccines against cholera. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2011</b> , 8, 701-10	24.2	49
127	Sublingual vaccination. <i>Hum Vaccin</i> , <b>2011</b> , 7, 110-4		47
126	Mucosal immunity and vaccination. <i>FEMS Microbiology Letters</i> , <b>1991</b> , 4, 1-9	2.9	47
125	Fucosyl-GM1 A ganglioside associated with small cell lung carcinomas. <i>Glycoconjugate Journal</i> , <b>1984</b> , 1, 43-49	3	47
124	A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori. <i>Vaccine</i> , <b>2011</b> , 29, 1235-41	4.1	46
123	Vaccines against enteric infections for the developing world. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , <b>2015</b> , 370,	5.8	43
122	Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. <i>Vaccine</i> , <b>1993</b> , 11, 1007-12	4.1	41
121	Immunological memory after immunization with oral cholera B subunit--whole-cell vaccine in Swedish volunteers. <i>Vaccine</i> , <b>1994</b> , 12, 1078-82	4.1	40
120	IMMUNODIFFUSION STUDIES ON ESCHERICHIA COLI. <i>Acta Pathologica Et Microbiologica Scandinavica</i> , <b>2009</b> , 76, 304-318		38
119	Interaction of Bordetella pertussis with mast cells, modulation of cytokine secretion by pertussis toxin. <i>Cellular Microbiology</i> , <b>2001</b> , 3, 181-8	3.9	38
118	Chlorpromazine reverses diarrhea in piglets caused by enterotoxigenic Escherichia coli. <i>Infection and Immunity</i> , <b>1979</b> , 24, 900-5	3.7	38
117	Novel carbohydrate binding site recognizing blood group A and B determinants in a hybrid of cholera toxin and Escherichia coli heat-labile enterotoxin B-subunits. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 3231-8	5.4	37
116	Ten years of the Global Alliance for Vaccines and Immunization: challenges and progress. <i>Nature Immunology</i> , <b>2010</b> , 11, 1069-72	19.1	36
115	Antitoxic cholera immunity in mice: influence of antigen deposition on antitoxin-containing cells and protective immunity in different parts of the intestine. <i>Infection and Immunity</i> , <b>1980</b> , 28, 17-23	3.7	36

114	Correlates of protection for enteric vaccines. <i>Vaccine</i> , <b>2017</b> , 35, 3355-3363	4.1	34
113	Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit. <i>Gene</i> , <b>1994</b> , 149, 211-7	3.8	34
112	Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission. <i>Pediatric Infectious Disease Journal</i> , <b>2008</b> , 27, 33-7	3.4	33
111	Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines. <i>Vaccine</i> , <b>1990</b> , 8, 469-72	4.1	33
110	Multiple attacks of hepatitis in drug addicts: biochemical, immunochemical, and morphologic characteristics. <i>Journal of Infectious Diseases</i> , <b>1973</b> , 127, 544-50	7	33
109	Structural basis for differential receptor binding of cholera and Escherichia coli heat-labile toxins: influence of heterologous amino acid substitutions in the cholera B-subunit. <i>Molecular Microbiology</i> , <b>1997</b> , 24, 489-97	4.1	32
108	B lymphocytes treated in vitro with antigen coupled to cholera toxin B subunit induce antigen-specific Foxp3(+) regulatory T cells and protect against experimental autoimmune encephalomyelitis. <i>Journal of Immunology</i> , <b>2012</b> , 188, 1686-97	5.3	31
107	Current status and future prospects for a vaccine against schistosomiasis. <i>Expert Review of Vaccines</i> , <b>2004</b> , 3, 315-28	5.2	31
106	Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. <i>International Immunology</i> , <b>1999</b> , 11, 1717-24	4.9	31
105	Genetic fusion of human insulin B-chain to the B-subunit of cholera toxin enhances in vitro antigen presentation and induction of bystander suppression in vivo. <i>Immunology</i> , <b>2002</b> , 106, 237-45	7.8	30
104	Differential expression of intestinal membrane transporters in cholera patients. <i>FEBS Letters</i> , <b>2007</b> , 581, 3183-8	3.8	29
103	Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 2299-307	7	29
102	Cholera toxin B subunit as transmucosal carrier-delivery and immunomodulating system for induction of antiinfectious and antipathological immunity. <i>Annals of the New York Academy of Sciences</i> , <b>1996</b> , 778, 185-93	6.5	29
101	Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. <i>Vaccine</i> , <b>2009</b> , 27, 6239-46	4.1	28
100	Nonparticipation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines. <i>American Journal of Epidemiology</i> , <b>1992</b> , 135, 865-74	3.8	28
99	Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. <i>International Immunology</i> , <b>1999</b> , 11, 1131-8	4.9	27
98	Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses. <i>Vaccine</i> , <b>2009</b> , 27, 1386-92	4.1	26
97	Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin. <i>Journal of Immunology</i> , <b>2006</b> , 176, 4902-13	5.3	26



96	A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection. <i>Vaccine</i> , <b>2003</b> , 21, 514-20	4.1	26
95	Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor. <i>European Journal of Immunology</i> , <b>2004</b> , 34, 1272-81	6.1	25
94	Dendritic cell vaccination protects mice against lethality caused by genital herpes simplex virus type 2 infection. <i>Journal of Reproductive Immunology</i> , <b>2001</b> , 50, 87-104	4.2	25
93	Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. <i>Vaccine</i> , <b>2000</b> , 19, 850-61	4.1	24
92	Synthesis in <i>Vibrio cholerae</i> and secretion of hepatitis B virus antigens fused to <i>Escherichia coli</i> heat-labile enterotoxin subunit B. <i>Gene</i> , <b>1991</b> , 99, 255-9	3.8	24
91	A novel adjuvanted capsule based strategy for oral vaccination against infectious diarrhoeal pathogens. <i>Journal of Controlled Release</i> , <b>2016</b> , 233, 162-73	11.7	24
90	Construction of a non-toxigenic <i>Escherichia coli</i> oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice. <i>Vaccine</i> , <b>2011</b> , 29, 8863-9	4.1	23
89	Murine antibody responses following systemic or mucosal immunization with viable or inactivated <i>Vibrio cholerae</i> . <i>Vaccine</i> , <b>2008</b> , 26, 6784-90	4.1	23
88	Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection. <i>Infection and Immunity</i> , <b>2004</b> , 72, 1184-7	3.7	23
87	Development of stable <i>Vibrio cholerae</i> O1 Hikojima type vaccine strains co-expressing the Inaba and Ogawa lipopolysaccharide antigens. <i>PLoS ONE</i> , <b>2014</b> , 9, e108521	3.7	23
86	Protective vaccination against genital herpes simplex virus type 2 (HSV-2) infection in mice is associated with a rapid induction of local IFN-gamma-dependent RANTES production following a vaginal viral challenge. <i>American Journal of Reproductive Immunology</i> , <b>2001</b> , 46, 420-4	3.8	22
85	Impaired IFN- $\gamma$ production after stimulation with bacterial components by natural killer cells from gastric cancer patients. <i>Experimental Cell Research</i> , <b>2011</b> , 317, 849-58	4.2	21
84	Characterization of enterotoxin and soluble hemagglutinin from <i>Vibrio mimicus</i> : identity with <i>V. cholerae</i> O1 toxin and hemagglutinin. <i>FEMS Microbiology Letters</i> , <b>1985</b> , 27, 17-22	2.9	21
83	Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated <i>Vibrio cholerae</i> . <i>Vaccine</i> , <b>2016</b> , 34, 2121-8	4.1	21
82	Cholera toxin expression by El Tor <i>Vibrio cholerae</i> in shallow culture growth conditions. <i>Microbial Pathogenesis</i> , <b>2014</b> , 66, 5-13	3.8	20
81	Construction of novel vaccine strains of <i>Vibrio cholerae</i> co-expressing the Inaba and Ogawa serotype antigens. <i>Vaccine</i> , <b>2011</b> , 29, 7505-13	4.1	20
80	Over-expression of major colonization factors of enterotoxigenic <i>Escherichia coli</i> , alone or together, on non-toxigenic <i>E. coli</i> bacteria. <i>Vaccine</i> , <b>2010</b> , 28, 6977-84	4.1	20
79	Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization. <i>Infection and Immunity</i> , <b>2001</b> , 69, 297-306	3.7	20



78	Tumor-cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small-cell lung carcinoma. <i>International Journal of Cancer</i> , <b>1991</b> , 49, 911-8	7.5	20
77	CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. <i>Current Opinion in Investigational Drugs</i> , <b>2004</b> , 5, 141-5		20
76	Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells. <i>Immunology</i> , <b>2006</b> , 118, 311-20	7.8	19
75	Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 33369-77	5.4	19
74	Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate. <i>Vaccine</i> , <b>2001</b> , 19, 3360-8	4.1	19
73	Diminished immunopathology in <i>Schistosoma mansoni</i> infection following intranasal administration of cholera toxin B-immunodominant peptide conjugate correlates with enhanced transforming growth factor-beta production by CD4 T cells. <i>Parasite Immunology</i> , <b>2002</b> , 24, 423-7	2.2	18
72	Enhanced immunological tolerance against allograft rejection by oral administration of allogeneic antigen linked to cholera toxin B subunit. <i>Clinical Immunology</i> , <b>2000</b> , 97, 130-9	9	18
71	When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks?. <i>Current Topics in Microbiology and Immunology</i> , <b>2014</b> , 379, 231-58	3.3	17
70	The design and analysis of cholera vaccine trials: recent lessons from Bangladesh. <i>International Journal of Epidemiology</i> , <b>1993</b> , 22, 724-30	7.8	17
69	Preclinical immunogenicity and protective efficacy of an oral <i>Helicobacter pylori</i> inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant. <i>Vaccine</i> , <b>2018</b> , 36, 6223-6230	4.1	16
68	Mucosal vaccination increases local chemokine production attracting immune cells to the stomach mucosa of <i>Helicobacter pylori</i> infected mice. <i>Vaccine</i> , <b>2012</b> , 30, 1636-43	4.1	16
67	Antibody responses in serum and lung to intranasal immunization with <i>Haemophilus influenzae</i> type b polysaccharide conjugated to cholera toxin B subunit and tetanus toxoid. <i>Apmis</i> , <b>1998</b> , 106, 800-6	3.4	16
66	Expression of cholera toxin under non-AKI conditions in <i>Vibrio cholerae</i> El Tor induced by increasing the exposed surface of cultures. <i>Journal of Bacteriology</i> , <b>2004</b> , 186, 1355-61	3.5	16
65	Enteric infections in an endemic area induce a circulating antibody-secreting cell response with homing potentials to both mucosal and systemic tissues. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 1594-9		16
64	Receptors for cholera toxin and <i>Escherichia coli</i> heat-labile enterotoxin revisited. <i>Progress in Brain Research</i> , <b>1994</b> , 101, 163-77	2.9	16
63	Important role for FcRIIB on B lymphocytes for mucosal antigen-induced tolerance and Foxp3+ regulatory T cells. <i>Journal of Immunology</i> , <b>2013</b> , 191, 4412-22	5.3	15
62	CD8- natural killer cells are greatly enriched in the human gastrointestinal tract and have the capacity to respond to bacteria. <i>Journal of Innate Immunity</i> , <b>2010</b> , 2, 294-302	6.9	15
61	CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice. <i>Journal of Reproductive Immunology</i> , <b>2005</b> , 68, 53-69	4.2	15

60	Cost of immunization with a locally produced, oral cholera vaccine in Viet Nam. <i>Vaccine</i> , <b>2001</b> , 19, 3720-54.1	4.1	15
59	Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli. <i>Gene</i> , <b>1995</b> , 165, 163-71	3.8	15
58	Effect of protein release rates from tablet formulations on the immune response after sublingual immunization. <i>European Journal of Pharmaceutical Sciences</i> , <b>2012</b> , 47, 695-700	5.1	14
57	Construction and expression of immunogenic hybrid enterotoxigenic Escherichia coli CFA/I and CS2 colonization fimbriae for use in vaccines. <i>Applied Microbiology and Biotechnology</i> , <b>2010</b> , 87, 1355-65	5.7	13
56	Expression of the Escherichia coli lamB gene in Vibrio cholerae. <i>Microbial Pathogenesis</i> , <b>1986</b> , 1, 283-8	3.8	13
55	Precipitating antibodies to E. coli O antigens: a suggested difference in the antibody response of infants and children with first and recurrent attacks of pyelonephritis. <i>Acta Paediatrica, International Journal of Paediatrics</i> , <b>1969</b> , 58, 506-12	3.1	13
54	Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India. <i>PLoS ONE</i> , <b>2014</b> , 9, e96499	3.7	13
53	Preparation and evaluation of a freeze-dried oral killed cholera vaccine formulation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2011</b> , 79, 508-18	5.7	12
52	Immunohistochemical detection of two small cell lung carcinoma-associated antigens defined by MAbs F12 and 123C3 in bronchoscopy biopsy tissues. <i>Apmis</i> , <b>1991</b> , 99, 797-802	3.4	12
51	Retrospective Analysis of Serotype Switching of Vibrio cholerae O1 in a Cholera Endemic Region Shows It Is a Non-random Process. <i>PLoS Neglected Tropical Diseases</i> , <b>2016</b> , 10, e0005044	4.8	12
50	Surface expression of Helicobacter pylori HpaA adhesion antigen on Vibrio cholerae, enhanced by co-expressed enterotoxigenic Escherichia coli fimbrial antigens. <i>Microbial Pathogenesis</i> , <b>2017</b> , 105, 177-184	3.8	11
49	An oral alpha-galactosylceramide adjuvanted vaccine induces protective IL-1R- and IL-17R-dependent Th1 responses. <i>Npj Vaccines</i> , <b>2019</b> , 4, 45	9.5	11
48	Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis. <i>Infection and Immunity</i> , <b>2000</b> , 68, 485-91	3.7	11
47	Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines. <i>Mucosal Immunology</i> , <b>2019</b> , 12, 1055-1064	9.2	10
46	Deficiency in Calcium-Binding Protein S100A4 Impairs the Adjuvant Action of Cholera Toxin. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1119	8.4	10
45	Cholera toxin induces a transient depletion of CD8+ intraepithelial lymphocytes in the rat small intestine as detected by microarray and immunohistochemistry. <i>Infection and Immunity</i> , <b>2005</b> , 73, 5595-602	3.7	10
44	Enterotoxin-specific immunoglobulin E responses in humans after infection or vaccination with diarrhea-causing enteropathogens. <i>Infection and Immunity</i> , <b>2000</b> , 68, 6077-81	3.7	10
43	Immunity to Vibrio cholerae Infection257-271		10

42	Vaccination with Bordetella pertussis-pulsed autologous or heterologous dendritic cells induces a mucosal antibody response in vivo and protects against infection. <i>Infection and Immunity</i> , <b>2001</b> , 69, 4120-27	3.7	9
41	Induction and expression of intestinal humoral immunity in HIV-infected individuals: prospects for vaccination against secondary enteric infections. <i>Pathobiology</i> , <b>1998</b> , 66, 176-82	3.6	9
40	IMMUNODIFFUSION STUDIES ON ESCHERICHIA COLI. <i>Acta Pathologica Et Microbiologica Scandinavica</i> , <b>2009</b> , 77, 727-738		7
39	3.8. Oral Vaccination, Mucosal Immunity and Oral Tolerance with Special Reference to Cholera Toxin <b>1996</b> , 437-458		7
38	Mucosal Immunity to Bacteria <b>2005</b> , 783-797		7
37	Preparation and preclinical evaluation of a freeze-dried formulation of a novel combined multivalent whole-cell/B-subunit oral vaccine against enterotoxigenic Escherichia coli diarrhea. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2016</b> , 108, 18-24	5.7	7
36	Adjuvants Enhance the Induction of Germinal Center and Antibody Secreting Cells in Spleen and Their Persistence in Bone Marrow of Neonatal Mice. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2214	8.4	6
35	A case for control of cholera in Africa by vaccination. <i>Lancet Infectious Diseases, The</i> , <b>2012</b> , 12, 818-9	25.5	6
34	Vibrio cholerae O139 capsular polysaccharide confers complement resistance in the absence or presence of antibody yet presents a productive target for cell lysis: implications for detection of bactericidal antibodies. <i>Microbial Pathogenesis</i> , <b>2009</b> , 47, 314-20	3.8	6
33	Phage display for site-specific immunization and characterization of high-risk human papillomavirus specific E7 monoclonal antibodies. <i>Journal of Immunological Methods</i> , <b>2008</b> , 337, 88-96	2.5	6
32	A clinical study of CA-50 as a tumour marker for monitoring of colorectal cancer. <i>Medical Oncology and Tumor Pharmacotherapy</i> , <b>1988</b> , 5, 165-71		6
31	Monoclonal Antibodies and Immunodetection Methods for Vibrio cholerae and Escherichia coli Enterotoxins <b>1986</b> , 77-97		6
30	Thermostability of the coating, antigen and immunostimulator in an adjuvanted oral capsule vaccine formulation. <i>International Journal of Pharmaceutics</i> , <b>2017</b> , 534, 60-70	6.5	5
29	Suppression of HIV replication in vitro by CpG and CpG conjugated to the non toxic B subunit of cholera toxin. <i>Current HIV Research</i> , <b>2008</b> , 6, 230-8	1.3	5
28	CpG oligodeoxynucleotides and mobilization of innate mucosal immunity: tasks and tactics. <i>Vaccine</i> , <b>2006</b> , 24 Suppl 2, S2-48-9	4.1	5
27	Changes in intestinal fluid transport and immune responses to enterotoxins due to concomitant parasitic infection. <i>Infection and Immunity</i> , <b>1980</b> , 30, 734-40	3.7	5
26	Development of Hillchol <sup>®</sup> , a low-cost inactivated single strain Hikojima oral cholera vaccine. <i>Vaccine</i> , <b>2020</b> , 38, 7998-8009	4.1	5
25	Requirement for Cyclic AMP/Protein Kinase A-Dependent Canonical NF $\kappa$ B Signaling in the Adjuvant Action of Cholera Toxin and Its Non-toxic Derivative mmCT. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 269	8.4	4

24	Helicobacter pylori Infection of the Gastric Mucosa <b>2015</b> , 985-1001		4
23	Detection of human papillomavirus oncoprotein E7 in liquid-based cytology. <i>Journal of General Virology</i> , <b>2012</b> , 93, 356-363	4.9	4
22	Adoptive transfer of mucosal T cells or dendritic cells from animals fed with cholera toxin B subunit alloantigen conjugate induces allogeneic T cell tolerance. <i>Advances in Experimental Medicine and Biology</i> , <b>2001</b> , 495, 271-5	3.6	4
21	B cells treated with CTB-p210 acquire a regulatory phenotype in vitro and reduce atherosclerosis in apolipoprotein E deficient mice. <i>Vascular Pharmacology</i> , <b>2018</b> , 111, 54-61	5.9	4
20	The subcellular location of antigen expressed by adenoviral vectors modifies adaptive immunity but not dependency on cross-presenting dendritic cells. <i>European Journal of Immunology</i> , <b>2011</b> , 41, 2185-96	6.1	3
19	Mucosal adjuvants based on cholera toxin and E. coli heat-labile enterotoxin <b>2006</b> , 235-252		3
18	An Update on Cholera Immunity and Current and Future Cholera Vaccines. <i>Tropical Medicine and Infectious Disease</i> , <b>2021</b> , 6,	3.5	3
17	Proteomic analysis of cholera toxin adjuvant-stimulated human monocytes identifies Thrombospondin-1 and Integrin- $\alpha$ as strongly upregulated molecules involved in adjuvant activity. <i>Scientific Reports</i> , <b>2019</b> , 9, 2812	4.9	3
16	Enzyme-linked immunosorbent assay for determination of antibodies to Vibrio cholerae toxin-coregulated pili. <i>Apmis</i> , <b>1992</b> , 100, 1027-32	3.4	2
15	Mucosal immunity and vaccination		2
14	Nasal administration of Schistosoma mansoni egg antigens-cholera toxin B subunit conjugate to infected mice reduces immunopathology and mortality. <i>Advances in Experimental Medicine and Biology</i> , <b>2001</b> , 495, 305-9	3.6	2
13	Vaccines against Bacterial Enteric Infections <b>2015</b> , 1047-1082		1
12	Expression of virulence factors by classical and El Tor Vibrio cholerae in vivo and in vitro. <i>FEMS Microbiology Ecology</i> , <b>1990</b> , 7, 221-228	4.3	1
11	A phase I/II study to evaluate safety, tolerability and immunogenicity of Hillchol $\square$ , an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh. <i>Vaccine</i> , <b>2021</b> , 39, 4450-4457	4.1	1
10	Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. <i>Vascular Pharmacology</i> , <b>2021</b> , 140, 106863	5.9	0
9	Cholera Immunity and Cholera Vaccination <b>2008</b> , 173-194		0
8	QUANTISATION OF VIBRIOCIDAL ANTIBODIES USING AGAR PLAQUE TECHNIQUES. <i>Acta Pathologica Et Microbiologica Scandinavica - Section B Microbiology and Immunology</i> , <b>2009</b> , 79B, 708-714		
7	Response to "questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003" <i>Vaccine</i> 2007;25(8):1353-4. <i>Vaccine</i> , <b>2007</b> , 25, 7981-3	4.1	

6 Studies on the sensitivity of *Proteus mirabilis* and *Proteus vulgaris* to sulphonamide and colistin alone and in combination. *Scandinavian Journal of Infectious Diseases*, **1970**, 2, 121-4

5 Engineered bacterial toxin vaccines and adjuvants **2006**, 1008-1018

4 Vaccine development for the control of cholera and related toxin-induced diarrhoeal diseases. *Novartis Foundation Symposium*, **1985**, 112, 242-70

3 Cholera Immunity and Development and Use of Oral Cholera Vaccines for Disease Control **2020**, 537-561

2 Cholera Vaccines **2018**, 185-197.e5

1 Diarrhea Caused by Bacteria **2018**, 252-260.e4